Accessibility Menu
Translational Development Acquisition Corp. logo

Translational Development Acquisition Corp.(NASDAQ) TDAC

Market Cap$209.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+8%
5 YearN/A
1 Year+5%
1 Month+0%
$10.85
+0.00%
+0.00Today
Translational Development Acquisition Corp. last closing stock price
MetricPriceDate
Last closeUSD 10.852026-08-31
Translational Development Acquisition Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.05%USD 10.852026-08-24
1 month+0.18%USD 10.832026-07-31
3 month+0.93%USD 10.752026-06-02
Year to date+3.43%USD 10.492025-12-31
1 year+4.93%USD 10.342025-08-29
Since inception+8.39%USD 10.012025-02-13

Translational Development Acquisition Corp. Financials at a Glance

Market Cap

$209.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$5.54M

EPS (TTM)

$0.25

P/E Ratio

42.80

Dividend

$0.00

Beta (Volatility)

0.22 (Low)

Price

$10.85

Volume

667.095

Open

$10.83

Previous Close

$10.85

Daily Range

$10.83 - $10.85

52-Week Range

$10.33 - $10.95

Estimated Earnings Date

May 15, 2026

TDAC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. helps private businesses become public companies. It looks for a strong business to buy and join. This process gives companies the money they need to grow.

Finding a Target

  • Business Combination Search: Identifying and evaluating potential merger targets for a shareholder-approved acquisition.
  • Capital Trust Account: Holding funds from investors to finance a future business deal; contained $157.3 million as of June 30, 2026.
  • Public Listing Platform: Providing private companies a path to the stock market through a merger process.

Strategic Paths to Growth

  • Entered a merger agreement with ProLogium Holding Inc. on May 27, 2026.
  • Signed a $50 million subscription agreement with Naetas Holding Limited in July 2026.
  • Extended its deadline to complete a business combination to August 24, 2026.
  • Converted 4.6 million Class B shares into Class A shares in June 2026.

What Sets TDAC Apart?

Translational Development operates as a blank check company, which is a shell entity created to buy an existing business. It uses funds held in a trust account to finance a merger with a private company.

By the Numbers

  • Net income was $946,982 for the three months ended June 30, 2026.
  • Market capitalization reached $180.1 million in the second quarter of 2026, up 1.7% year over year.
  • Shareholders redeemed $27.8 million in shares at a price of $10.70 per share in June 2026.
  • The price-to-earnings ratio was 66.8 in the second quarter of 2026.
  • Management reported substantial doubt about the company's ability to continue as a going concern as of June 30, 2026.

Bottom Line

Translational Development has moved from searching for a target to pursuing a specific merger with ProLogium. Its future depends on completing this deal before its mandatory 2027 liquidation deadline.

AI Generated • Aug 15, 2026

Industry

Capital Markets

Sector

Financials

Employees

2

CEO

Michael B. Hoffman, MBA

Website

www.translational-development.com

Headquarters

New York City, NY 10028, US

TDAC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3.28%

Return on Capital

-0.54%

Return on Assets

3.52%

Earnings Yield

2.34%

Dividend Yield

0.00%

Payout Ratio

58.20%

Stock Overview

Market Cap

$209.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

19.31M

Volume

667.095

Avg. Volume

61.65K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.32M

EBITDA

-$1.32M

Operating Cash Flow

-$849.38K

Capital Expenditure

$0.00

Free Cash Flow

-$849.38K

Cash & ST Invst.

$85.88K

Total Debt

$1.10M

Translational Development Acquisition Corp. Performance Analysis

Translational Development Acquisition Corp. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Translational Development Acquisition Corp. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Translational Development Acquisition Corp. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00N/A
20232023-12-31USD -0.03920.0%
20242024-12-31USD -0.00-87.5%
20252025-12-31USD 0.29N/A
Translational Development Acquisition Corp. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.0%
Q42025-12-31-9.0%
Q12026-03-31-16.5%
Q22026-06-30-27.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$209.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$104.75M

N/A

Employees

2

N/A

Net Income

$946.98K

-41.7%

EBITDA

-$661.05K

-198.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$85.88K

+143.6%

Total Debt

$1.10M

-79.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.10M

-79.2%

Return on Assets

3.52%

N/A

Return on Invested Capital

-0.85%

N/A

Free Cash Flow

-$338.75K

-97.7%

Operating Cash Flow

-$338.75K

-97.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CEPOCantor Equity Partners I, Inc. Class A Ordinary Shares
$10.75+0.00%
NTWONewbury Street II Acquisition Corp
$10.89-0.37%
MACIMelar Acquisition Corp. I
$10.99+0.37%
CEPCantor Equity Partners, Inc. Class A Ordinary Shares
$14.27-1.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$219.72-0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.36-0.06%
INTCIntel
$88.83-0.01%
BIAFbioAffinity Technologies
$6.37+0.40%

Questions About TDAC

What is the current price of Translational Development Acquisition Corp.?

Translational Development Acquisition Corp. is trading at $10.85 per share.

What is the 52-week range for Translational Development Acquisition Corp.?

Over the past 52 weeks, Translational Development Acquisition Corp. has traded between $10.33 and $10.95.

How much debt does Translational Development Acquisition Corp. have?

As of the most recent reporting period, Translational Development Acquisition Corp. reported total debt of $1.10M.

How much cash does Translational Development Acquisition Corp. have on hand?

Translational Development Acquisition Corp. reported $85.88K in cash and cash equivalents in its most recent financial results.

What is Translational Development Acquisition Corp.’s dividend yield?

Translational Development Acquisition Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services